Results showed that a significantly longer DFS was observed with adjuvant gefitinib therapy compared with vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.